Literature DB >> 29987457

Clinical parameters, LysoGb3, podocyturia, and kidney biopsy in children with Fabry disease: is a correlation possible?

Juan Politei1, Valeria Alberton2, Oscar Amoreo2, Norberto Antongiovanni3, Maria Nieves Arán2, Marcelo Barán2, Gustavo Cabrera4, Silvia Di Pietrantonio2, Consuelo Durand5, Alejandro Fainboim6, Joaquin Frabasil5, Fernando Gomez Pizarro7, Roberto Iotti8, Miguel Liern6, Fernando Perretta3, Diego Ripeau9, Fernanda Toniolo10, Hernan Trimarchi11, Dana Velasques Rivas5, Eric Wallace12, Andrea Beatriz Schenone5.   

Abstract

BACKGROUND: Fabry disease is an X-linked lysosomal storage disorder caused by α-galactosidase enzyme deficiency. We present clinical, biochemical, and histologic findings in children with classical phenotypic presentation of Fabry disease.
METHODS: A retrospective analysis was performed using charts from 14 children with confirmed diagnosis. Clinical parameters were evaluated. Globotriaosylsphingosine -lysoGb3- detection in plasma, podocyturia, and kidney biopsy were carried out in all cases.
RESULTS: All patients except one demonstrated at least one symptom of Fabry disease. LysoGb3 levels were above the normal range in all patients. Podocyturia was documented in all patients. Kidney biopsy revealed glomerular, interstitial, vascular, and tubular changes on light microscopy in nearly all patients. Electron microscopy showed podocyte inclusions in all patients.
CONCLUSIONS: No difference in symptomatology was discernible between boys and girls. Podocyturia was detectable in children serving as a possible early marker of kidney injury. LysoGb3 was elevated in all cases, emphasizing the importance for diagnosis especially in female patients with normal αGal A activity. A possible association between lysoGb3 and symptom severity and histological involvement in kidney biopsy should be assessed in prospective studies with enough statistical power to determine if lysoGb3 can be used to predict nephropathy in children with Fabry disease.

Entities:  

Keywords:  Fabry disease; Globotriaosylsphingosine; Podocyturia

Mesh:

Substances:

Year:  2018        PMID: 29987457     DOI: 10.1007/s00467-018-4006-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  36 in total

1.  Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers.

Authors:  Gabor E Linthorst; Anouk C Vedder; Johannes M F G Aerts; Carla E M Hollak
Journal:  Clin Chim Acta       Date:  2005-03       Impact factor: 3.786

2.  X-chromosome inactivation in female patients with Fabry disease.

Authors:  L Echevarria; K Benistan; A Toussaint; O Dubourg; A A Hagege; D Eladari; F Jabbour; C Beldjord; P De Mazancourt; D P Germain
Journal:  Clin Genet       Date:  2015-06-22       Impact factor: 4.438

3.  Quantitating glomerular endothelial fenestration: an unbiased stereological approach.

Authors:  Behzad Najafian; Michael Mauer
Journal:  Am J Nephrol       Date:  2011-06-10       Impact factor: 3.754

4.  Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease.

Authors:  Markus Niemann; Arndt Rolfs; Stefan Störk; Bart Bijnens; Frank Breunig; Meinrad Beer; Georg Ertl; Christoph Wanner; Frank Weidemann
Journal:  Circ Cardiovasc Genet       Date:  2014-01-06

5.  Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease.

Authors:  Behzad Najafian; Einar Svarstad; Leif Bostad; Marie-Claire Gubler; Camilla Tøndel; Chester Whitley; Michael Mauer
Journal:  Kidney Int       Date:  2010-12-15       Impact factor: 10.612

6.  Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.

Authors:  Raphael Schiffmann; Derralynn A Hughes; Gabor E Linthorst; Alberto Ortiz; Einar Svarstad; David G Warnock; Michael L West; Christoph Wanner
Journal:  Kidney Int       Date:  2016-12-18       Impact factor: 10.612

Review 7.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

8.  Paediatric Fabry disease: prognostic significance of ocular changes for disease severity.

Authors:  Gisela Kalkum; Susanne Pitz; Nesrin Karabul; Michael Beck; Guillem Pintos-Morell; Rossella Parini; Marianne Rohrbach; Svetlana Bizjajeva; Uma Ramaswami
Journal:  BMC Ophthalmol       Date:  2016-11-16       Impact factor: 2.209

9.  Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy.

Authors:  Brent Fall; C Ronald Scott; Michael Mauer; Stuart Shankland; Jeffrey Pippin; Jonathan A Jefferson; Eric Wallace; David Warnock; Behzad Najafian
Journal:  PLoS One       Date:  2016-12-16       Impact factor: 3.240

10.  Significant improvement in Fabry disease podocytopathy after 3 years of treatment with agalsidase beta.

Authors:  Shuichi Ito; Masao Ogura; Koichi Kamei; Kentaro Matsuoka; David G Warnock
Journal:  Pediatr Nephrol       Date:  2016-04-29       Impact factor: 3.651

View more
  5 in total

1.  The Changing Landscape of Fabry Disease.

Authors:  Einar Svarstad; Hans Peter Marti
Journal:  Clin J Am Soc Nephrol       Date:  2020-03-04       Impact factor: 8.237

Review 2.  Recommendations for the diagnosis and management of Fabry disease in pediatric patients: a document from the Rare Diseases Committee of the Brazilian Society of Nephrology (Comdora-SBN).

Authors:  Maria Helena Vaisbich; Luís Gustavo Modelli de Andrade; Cassiano Augusto Braga Silva; Fellype de Carvalho Barreto
Journal:  J Bras Nefrol       Date:  2022 Apr-Jun

3.  Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients.

Authors:  Dominique P Germain; Alain Fouilhoux; Stéphane Decramer; Marine Tardieu; Pascal Pillet; Marc Fila; Serge Rivera; Georges Deschênes; Didier Lacombe
Journal:  Clin Genet       Date:  2019-06-06       Impact factor: 4.438

4.  α-Galactosidase a Deficiency in Fabry Disease Leads to Extensive Dysregulated Cellular Signaling Pathways in Human Podocytes.

Authors:  Ulrich Jehn; Samet Bayraktar; Solvey Pollmann; Veerle Van Marck; Thomas Weide; Hermann Pavenstädt; Eva Brand; Malte Lenders
Journal:  Int J Mol Sci       Date:  2021-10-20       Impact factor: 5.923

5.  Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis.

Authors:  Christoph Wanner; Ulla Feldt-Rasmussen; Ana Jovanovic; Aleš Linhart; Meng Yang; Elvira Ponce; Eva Brand; Dominique P Germain; Derralynn A Hughes; John L Jefferies; Ana Maria Martins; Albina Nowak; Bojan Vujkovac; Frank Weidemann; Michael L West; Alberto Ortiz
Journal:  ESC Heart Fail       Date:  2020-02-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.